Skip to main content

Table 1 Comparison of Selected Drugs in Terms of a Response

From: Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Agent Splenomegaly1 Anemia2 Symptoms3 References
IMiDs     
 Thalidomide 19 % 43 % NS [15]
 (Celgene Corp., Summit, NJ, USA) 8 % 22 % NR [16]
 Lenalidomide 10 % 19 % NR [48]
 (Celgene Corp., Summit, NJ, USA) 42 % 30 % NR [18]
 Pomalidomide 0 ≤40 % NR [21]
 (Celgene Corp., Summit, NJ, USA) 11 % 37 % NR [22]
0 17 % NR [23]
JAK Inhibitors     
 Ruxolitinib (INCB018424) 44 % 14 % 52–82 % [42]
 (Incyte Corporation, Wilmington, DE, USA—US rights; Novartis AG, Basel, Switzerland—ex-US rights) 42 %4 NR 46 %5 [43]
32 %5 NR NR [44]
 SAR302503 (TG101348) (Sanofi, Paris, France) 39 % 0 25–89 % [47]
 CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada) 45 50 % NR [49]
 Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore) 44 % <1 % NR [50]
 Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA) 18 % 1 % NR [51]
mTOR Inhibitor     
Everolimus (RAD001) (Novartis AG, Basel, Switzerland) 17 % <1 % 69 %5 [52]
  1. IMiDs = immunomodulatory drugs; NR = not reported; NS = not significant.
  2. 1Percentage of patients achieving ≥50 % reduction in spleen size, unless otherwise specified.
  3. 2Percentage of patients achieving a ≥2 g/dL increase in Hb, unless otherwise specified.
  4. 3Percentage of patients achieving complete resolution of symptoms.
  5. 4Percentage of patients achieving ≥35 % reduction in spleen volume.
  6. 5Percentage of patients achieving ≥50 % reduction in total symptom score on the Myelofibrosis Symptom Assessment Form.